Katie de Lange
Katie de Lange
Katie leads the Population Analysis team, leveraging large-scale genomic datasets to better understand human health and disease. She has a background in computational biology, getting her BCMS(Hons) degree in computer science from the University of Waikato, New Zealand and her PhD in statistical genetics from the University of Cambridge (based at the Wellcome Trust Sanger Institute).
Most recently she has spent several years in the drug discovery industry, including at Vertex Pharmaceuticals in Boston and the Novartis Institutes for Biomedical Research in Switzerland, where she was working to translate genomic insights into novel therapeutics.
Most recently she has spent several years in the drug discovery industry, including at Vertex Pharmaceuticals in Boston and the Novartis Institutes for Biomedical Research in Switzerland, where she was working to translate genomic insights into novel therapeutics.
Katie leads the Population Analysis team, leveraging large-scale genomic datasets to better understand human health and disease. She has a background in computational biology, getting her BCMS(Hons) degree in computer science from the University of...
Katie leads the Population Analysis team, leveraging large-scale genomic datasets to better understand human health and disease. She has a background in computational biology, getting her BCMS(Hons) degree in computer science from the University of Waikato, New Zealand and her PhD in statistical genetics from the University of Cambridge (based at the Wellcome Trust Sanger Institute).
Most recently she has spent several years in the drug discovery industry, including at Vertex Pharmaceuticals in Boston and the Novartis Institutes for Biomedical Research in Switzerland, where she was working to translate genomic insights into novel therapeutics.
Most recently she has spent several years in the drug discovery industry, including at Vertex Pharmaceuticals in Boston and the Novartis Institutes for Biomedical Research in Switzerland, where she was working to translate genomic insights into novel therapeutics.
Share //
